Literature DB >> 15943767

In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals.

M Manfredi1, M J McCullough, S Conti, L Polonelli, P Vescovi, Z M Al-Karaawi, S R Porter.   

Abstract

BACKGROUND/AIMS: A monoclonal killer anti-idiotypic antibody (mAbK10) and a synthetic killer peptide, acting as internal images of a microbicidal, wide-spectrum yeast killer toxin (KT) have been recently shown to express candidacidal in vitro and an in vivo therapeutic activity against experimental mucosal and systemic candidosis models caused by a reference strain of Candida albicans (10S).
MATERIAL AND METHODS: The in vitro candidacidal activity of mAbK10 and synthetic killer peptide was compared using a colony forming unit assay against a large number of isolates of different Candida spp., obtained from oral saliva of adult diabetic (type 1 and 2) and nondiabetic subjects from Parma (Italy) and London (UK).
RESULTS: Both the KT-mimics exerted a strong dose-dependent candidacidal activity, probably mediated by the interaction with beta-glucan KT receptors on target yeast cells, against all the tested strains, regardless of their species and pattern of resistance to conventional antifungal agents.
CONCLUSIONS: These observations open new perspectives in the design and production of candidacidal compounds whose mechanism reflects that exerted in nature by killer yeasts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15943767     DOI: 10.1111/j.1399-302X.2005.00217.x

Source DB:  PubMed          Journal:  Oral Microbiol Immunol        ISSN: 0902-0055


  2 in total

1.  Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity.

Authors:  Elena Gabrielli; Eva Pericolini; Elio Cenci; Federica Ortelli; Walter Magliani; Tecla Ciociola; Francesco Bistoni; Stefania Conti; Anna Vecchiarelli; Luciano Polonelli
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

2.  Antibody Peptide based antifungal immunotherapy.

Authors:  Walter Magliani; Stefania Conti; Laura Giovati; Pier Paolo Zanello; Martina Sperindè; Tecla Ciociola; Luciano Polonelli
Journal:  Front Microbiol       Date:  2012-06-01       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.